SCHEMBL2527445

SCHEMBL2527445

[C]1c2ccccc2C=CC2C=CC=CC12

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL435482 0.64
SCHEMBL2102618 0.63
SCHEMBL9620918 0.63
SCHEMBL8677188 0.60 KDM4E (0.40)
SCHEMBL3667828 0.59 IDO1 (0.35)
SCHEMBL3118101 0.59 GAA (0.39)
SCHEMBL5100128 0.59 KDM4E (0.30)
SCHEMBL4190469 0.59 ALOX5 (0.32)
SCHEMBL8616259 0.59
SCHEMBL8131491 0.58 CYP2D6 (0.35)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1689729-A1 TETRONIC AND TETRAMIC ACIDS AS INHIBITORS OF BETA-SECREASE F. Hoffmann-La Roche AG (CH) 2006-08-16 EP claimed
WO-2005058857-A1 TETRONIC AND TETRAMIC ACIDS AS INHIBITORS OF BETA-SECREASE F. HOFFMANN-LA ROCHE AG (CH) 2005-06-30 WO claimed
US-5231104-A Anticholinergic PFIZER INC. (US) 1993-07-27 US claimed
EP-2379505-A1 MODIFIED CHLOROQUINES WITH SINGLE RING MOIETY OR FUSED RING MOIETY Designmedix, Inc. (US) 2011-10-26 EP disclosed
WO-2010065932-A1 MODIFIED CHLOROQUINES WITH SINGLE RING MOIETY OR FUSED RING MOIETY DESIGNMEDIX, INC. (US) 2010-06-10 WO disclosed
EP-1438309-A1 QUINUCLIDINE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES AS M2 AND/OR M3 MUSCARINIC RECEPTOR INHIBITORS UCB, S.A. (BE) 2004-07-21 EP disclosed
EP-1315736-A2 NUCLEOSIDE DERIVATIVES FOR THE TREATMENT OF HEPATITIS C F. HOFFMANN-LA ROCHE AG (CH) 2003-06-04 EP disclosed
WO-2003033495-A1 QUINUCLIDINE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES AS M2 AND/OR M3 MUSCARINIC RECEPTOR INHIBITORS UCB, S.A. (BE) 2003-04-24 WO disclosed
WO-2002018404-A2 NUCLEOSIDE DERIVATIVES FOR THE TREATMENT OF HEPATITIS C F. HOFFMANN-LA ROCHE AG (CH) 2002-03-07 WO disclosed